News
Stay up to date with the latest news, trials, and upcoming events from ANT
Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment
Financing supports the approval of U.S. Investigational Device Exemption (IDE), coronary clinical advancement, and expansion into below-the-knee peripheral (BTK) applications.
Advanced Nanotherapies Announces Positive Results in its First-in-Human Trial And Plans for U.S. Early Feasibility Study for Sirplux™ Duo Drug-Coated Balloon
Advanced Nanotherapies Announces Positive Results in its First-in-Human Trial And Plans for U.S. Early Feasibility Study for Sirplux™ Duo Drug-Coated BalloonFirst-of-its-kind Dual-Drug Therapy for Coronary De Novo Disease Moves Toward U.S. Clinical PhaseNovel...
Advanced NanoTherapies (ANT) Secures $4M Strategic Investment to Accelerate Clinical Development of SirPlux Duo Drug-Coated Balloon (DCB)for Treating de novo Coronary Artery Disease (CAD)
Advanced NanoTherapies Inc. (ANT), a clinical-stage medical device company committed to solving the most significant challenges in vascular disease through the creative applications of nanotechnology, today announced a $4M Series A extension from a prominent undisclosed strategic medical device company.
Advanced NanoTherapies’ SirPlux Duo Drug-Coated Balloon Receives FDA Breakthrough Designation for Small Vessel Coronary Artery Disease
Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease’s most significant challenges through the creative applications of nanotechnology, today announced the U.S. Food and Drug Administration (FDA) has granted the company a…
Advanced NanoTherapies Announces Closing of Oversubscribed $7.2 Million Series A Financing
Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease’s most significant challenges through the creative applications of nanotechnology, today announced the closing of its oversubscribed $7.2 million Series A equity financing
SirPlux Duo Receives Breakthrough Designation
SirPlux Duo Receives Breakthrough DesignationOn May 28, 2021, the US Food and Drug Administration (FDA) granted Advanced NanoTherapies Breakthrough Designation for its SirPlux Duo device. SirPlux Duo is a drug-coated balloon (DCB) that leverages nanotechnology to...
Advanced NanoTherapies Raises $5.3 Million in Seed-Round
Advanced NanoTherapies Raises $5.3 Million in Seed-RoundCompany accelerates development of its nanoparticle-based drug delivery technology platform to treat peripheral artery disease and other applicationsLOS GATOS, Calif. – October 13, 2020 – Advanced NanoTherapies,...